Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking.
Dr Kindermann and colleagues from the Netherlands investigated the predictive value of fecal calprotectin, and CRP for symptomatic relapse in pediatric IBD in clinical remission.
In this cross-sectional cohort study, patients <18 years with Crohn's disease or ulcerative colitis in clinical remission ≥3 months were included.
At baseline, clinical and biochemical disease activity were assessed using the abbreviated-Pediatric Crohn's Disease Activity Index or Pediatric Ulcerative Colitis Activity Index, and fecal calprotectin and CRP respectively.
The team retrospectively assessed disease course over the subsequent 12 months was retrospectively.
|The optimal CRP cut-off was 1.0 mg/L, with a negative predictive value of 94%|
|Alimentary Pharmacology & Therapeutics|
In total, 114 patients were included.
The researchers found that baseline fecal calprotectin was higher in patients that developed symptomatic relapse.
Baseline fecal calprotectin was predictive of symptomatic relapse within 6 months, with good predictive accuracy.
The team noted that optimal fecal calprotectin cut-off was 350 μg/g, with positive and negative predictive value of 41% and 96%.
Baseline CRP was higher in patients that developed symptomatic relapse.
The researchers observed that baseline CRP was predictive of symptomatic relapse within 6 months from baseline, with fair predictive accuracy.
The team found that the optimal CRP cut-off was 1.0 mg/L, with positive and negative predictive values of 21% and 94%.
Dr Kindermann's team concludes, "Fecal calprotectin and CRP are predictive of symptomatic relapse, and may be valuable in management of pediatric IBD in clinical remission."